Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial

1. Sigurgeirsson, B.
2. Browning, J.
3. Tyring, S.
4. Szepietowski, J.C.
5. Rivera-Díaz, R.
6. Effendy, I.
7. Keefe, D.
8. Bruin, G.
9. Paguet, B.
10. Fu, R.
11. Hampele, I.
12. Reinhardt, M.
13. Patekar, M.